"Tamoxifen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
| Descriptor ID |
D013629
|
| MeSH Number(s) |
D02.455.426.559.389.150.700.900
|
| Concept/Terms |
ICI-46474- ICI-46474
- ICI 46474
- ICI46474
- ICI-46,474
- ICI 46,474
- ICI46,474
|
Below are MeSH descriptors whose meaning is more general than "Tamoxifen".
Below are MeSH descriptors whose meaning is more specific than "Tamoxifen".
This graph shows the total number of publications written about "Tamoxifen" by people in this website by year, and whether "Tamoxifen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 2 | 4 |
| 1997 | 5 | 4 | 9 |
| 1998 | 4 | 2 | 6 |
| 1999 | 2 | 4 | 6 |
| 2000 | 4 | 2 | 6 |
| 2001 | 1 | 1 | 2 |
| 2003 | 5 | 3 | 8 |
| 2004 | 8 | 1 | 9 |
| 2005 | 8 | 8 | 16 |
| 2006 | 4 | 3 | 7 |
| 2007 | 0 | 2 | 2 |
| 2008 | 2 | 1 | 3 |
| 2009 | 5 | 3 | 8 |
| 2010 | 3 | 5 | 8 |
| 2011 | 5 | 4 | 9 |
| 2012 | 4 | 6 | 10 |
| 2013 | 1 | 5 | 6 |
| 2014 | 3 | 7 | 10 |
| 2015 | 2 | 2 | 4 |
| 2016 | 3 | 4 | 7 |
| 2017 | 1 | 7 | 8 |
| 2018 | 1 | 5 | 6 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 5 | 6 |
| 2021 | 1 | 4 | 5 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 0 | 1 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tamoxifen" by people in Profiles.
-
17?-Hydroxysteroid dehydrogenases 1 and 2: potential markers for breast cancer recurrence and tamoxifen resistance among premenopausal women diagnosed with breast cancer in Denmark. Breast Cancer Res. 2025 Dec 30; 28(1):28.
-
A mouse model engineered to spatiotemporally control Cre expression in progesterone receptor positive cells?. Biol Reprod. 2025 Jul 13; 113(1):83-96.
-
The Population-level Effect of Adjuvant Therapies on Breast Cancer Recurrence: Application of the Trend-in-Trend Design. Epidemiology. 2024 09 01; 35(5):660-666.
-
Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial). BMC Cancer. 2023 Sep 14; 23(1):865.
-
Nonestrogen Therapies for Treatment of Genitourinary Syndrome of Menopause: A Systematic Review. Obstet Gynecol. 2023 09 01; 142(3):555-570.
-
Steroid receptor coactivator 3 is a key modulator of regulatory T cell-mediated tumor evasion. Proc Natl Acad Sci U S A. 2023 06 06; 120(23):e2221707120.
-
A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer. Cancer Res. 2022 10 17; 82(20):3673-3686.
-
14-3-3t drives estrogen receptor loss via ERa36 induction and GATA3 inhibition in breast cancer. Proc Natl Acad Sci U S A. 2022 10 25; 119(43):e2209211119.
-
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer. J Clin Oncol. 2022 08 10; 40(23):2557-2567.
-
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer. Sci Rep. 2022 02 04; 12(1):1972.